Anti-VLA-4 monoclonal antibody R1-2

Drug Profile

Anti-VLA-4 monoclonal antibody R1-2

Alternative Names: Anti-alpha-4-integrin monoclonal antibody R1-2; Anti-integrin-alpha-4 monoclonal antibody R1-2

Latest Information Update: 10 Aug 2000

Price : $50

At a glance

  • Originator Harvard Medical School; Stanford University
  • Developer Biogen Idec; Harvard Medical School; Stanford University
  • Class Monoclonal antibodies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 10 Aug 2000 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top